Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung

[1]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[2]  T. Chou,et al.  Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma , 2013, Annals of surgery.

[3]  Biao He,et al.  A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies , 2012, The Lancet.

[4]  K. Nagai,et al.  Prognostic impact of histology on early-stage non-small cell lung cancer. , 2011, Chest.

[5]  Morihito Okada,et al.  Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. , 2011, The Journal of thoracic and cardiovascular surgery.

[6]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[7]  S. Shiono,et al.  Positron Emission Tomography/Computed Tomography and Lymphovascular Invasion Predict Recurrence in Stage I Lung Cancers , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Kyung Soo Lee,et al.  Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. , 2010, Lung cancer.

[9]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[10]  M. Noguchi.  Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications , 2010, Cancer and Metastasis Reviews.

[11]  Dong Sun Kim,et al.  Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Sung,et al.  The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma. , 2009, European Journal of Cardio-Thoracic Surgery.

[13]  David J Sugarbaker,et al.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Marcin Skrzypski,et al.  A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[15]  A. Marchetti,et al.  Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. , 2007, The Journal of clinical investigation.

[16]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[17]  T. Naruke,et al.  Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.

[18]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[19]  Kenji Suzuki,et al.  Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. , 2006, The Annals of thoracic surgery.

[20]  Y. Nishiwaki,et al.  Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. , 2005, The Journal of thoracic and cardiovascular surgery.

[21]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[22]  S. Sone,et al.  CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. , 2003, AJR. American journal of roentgenology.

[23]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[24]  K Kuriyama,et al.  Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. , 2001, Lung cancer.

[25]  A. Dujon,et al.  Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. , 2001, The Annals of thoracic surgery.

[26]  K. Yasumoto,et al.  Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. , 1998, The Journal of thoracic and cardiovascular surgery.

[27]  K. Sugimachi,et al.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. , 1991, European journal of cancer.

[28]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[29]  M. L. R. D. Christenson,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2012 .

[30]  L. Tanoue.  CT Screening for Lung Cancer: Five-year Prospective Experience , 2007 .